Literature DB >> 2733939

Serial changes in the 50-g oral glucose test in pregnancy: implications for screening.

W J Watson1.   

Abstract

To quantitate the effect of advancing pregnancy on the screening test for gestational diabetes, 550 patients were given a 50-g oral glucose screening test at 20, 28, and 34 weeks' gestation. A significant increase in the plasma glucose value was found, with a mean increase of 1.1 +/- 1.9 mg/dL per week from 20-34 weeks' gestation (r = 0.39, P less than .01). Only 34 patients (6.2%) had a positive screening test at 20 weeks' gestation, and it appears that routine screening in a low-risk population at 20 weeks is not warranted. Sixty patients (10.9%) with a negative screening test at 20 weeks had a positive test at 28 weeks. Forty-four patients (8.0%) with a negative test at 28 weeks had a subsequent positive test at 34 weeks. The overall incidence of gestational diabetes in this population was 4.9%. Currently, screening is recommended at 24-28 weeks for all pregnancies that have not been previously identified as having glucose intolerance. Eleven percent of the gestational diabetics in our population would have been undetected had we screened only at 24-28 weeks. This quantitative information may be helpful in deciding whether rescreening later in pregnancy is indicated.

Entities:  

Mesh:

Year:  1989        PMID: 2733939

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  An abnormal screening glucose challenge test in pregnancy predicts postpartum metabolic dysfunction, even when the antepartum oral glucose tolerance test is normal.

Authors:  Ravi Retnakaran; Ying Qi; Mathew Sermer; Philip W Connelly; Anthony J G Hanley; Bernard Zinman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-10-21       Impact factor: 3.478

Review 2.  Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged?

Authors:  Teri L Hernandez; Jacob E Friedman; Rachael E Van Pelt; Linda A Barbour
Journal:  Diabetes Care       Date:  2011-07       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.